NMPA Notice 2016 No. 61, Annex 1
Guideline for selecting and determining reference products for conventional oral solid dosage forms
Current edition
2016 (notice dated 18 March 2016)
Current edition
2016 (notice dated 18 March 2016)
About this standard
Explains how the reference product for the generic quality and efficacy consistency evaluation is chosen, filed and confirmed.
Recognition by market
Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts
No market listing is published yet.
Testing requirements that cite it
Open the market page and its pathway pages for the full requirement, protocol and report content
China
- Reference product for generic bioequivalence and consistency evaluationBioequivalence · Not stated
Related standards: JP guideline for bioequivalence studies of generic products, MHRA comparator product guidance, CPMP/EWP/QWP/1401/98 Rev 1, JP BE guideline, formulation changes (oral solid), NMPA Notice 2016 No. 61, Annex 3, FDA BE guidance for ANDAs (PK endpoints), HC comparative bioavailability conduct guidance, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9, M13A. See all standards.